Evaluating the Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for the Treatment of Influenza in Adult Outpatients in Hong Kong: A Cost‐Effectiveness Analysis

Baloxavir marboxil, an antiviral used only in private hospitals in Hong Kong since February 2019 for treating influenza, is recognized for its efficacy against strains resistant to standard antiviral agents, providing an alternative to neuraminidase inhibitors such as oseltamivir.